Comparison of effects of amlodipine and angiotensin receptor blockers on the intima–media thickness of carotid arterial wall (AAA study: Amlodipine vs. ARB in atherosclerosis study)

Ikeda, Hiroki; Minamikawa, Jun; Nakamura, Yoshio; Honjo, Sachiko; Hamamoto, Yoshiyuki; Wada, Yoshiharu; Nabe, Kouichiro; Koshiyama, Hiroyuki

doi:10.1016/j.diabres.2008.10.014

Cited by 30 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IMT measurement was calculated as the mean of three measurements including one at the site of the greatest thickness and two at sites 1 cm proximal and 1 cm distal to the first site. 24 However, in another study of 100 untreated hypertensive patients, after 12 months of follow-up, neither amlodipine (n¼50) nor valsartan (n¼50) significantly influenced carotid maximum IMT. 19 Two trials studied proteinuria or albuminuria using two different CCBs (efonidipine 25 and amlodipine 19 ) in comparison with ACE inhibitors 25 (enalapril, lisinopril or imidapril) and an ARB (valsartan).…”

Section: Protection Against Target Organ Damagementioning

confidence: 96%

“…The sample size ranged between 22 and 183. The study subjects had hypertension in all 12 trials; in several trials, study participants had co-morbid conditions such as type 2 diabetes mellitus, 24,26 coronary artery disease 27 and renal impairment. 25 Twelve trials included 14 CCB groups and 13 control groups.…”

Section: Protection Against Target Organ Damagementioning

confidence: 99%

“…The control drug was an ACE inhibitor in 6 trials, an ARB in 6 trials and a b blocker in 1 trial. These study drugs were initiated with the standard dose; in 7 trials 15,19,21,24,25,27,31 they were titrated to the high dose(s), and in 3 trials 19,21,27 they were also combined with additional non-study antihypertensive drugs to achieve the goal blood pressure, usually below 140/90 mm Hg of the conventional blood pressure.…”

Section: Protection Against Target Organ Damagementioning

confidence: 99%

“…The relative change tended to be greater for patients taking cilnidipine than for those taking quinapril (10.6 vs. 7.6%; P¼0.09). 29 Two trials studied carotid IMT using amlodipine in comparison with ARBs (candesartan, 24 losartan, 24 telmisartan 24 or valsartan 19,24 ).…”

Section: Protection Against Target Organ Damagementioning

confidence: 99%

See 3 more Smart Citations

Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association

et al. 2011

View full text Add to dashboard Cite

Section: Protection Against Target Organ Damagementioning

confidence: 96%

Section: Protection Against Target Organ Damagementioning

confidence: 99%

Section: Protection Against Target Organ Damagementioning

confidence: 99%

Section: Protection Against Target Organ Damagementioning

confidence: 99%

See 2 more Smart Citations

Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association

et al. 2011

View full text Add to dashboard Cite

“…Nakamura et al 35 recently showed that telmisartan was superior to amlodipine in protecting the worsening of IMT in Japanese hypertensive patients with moderate renal insufficiency, which is partly compatible with our results. In contrast, Ikeda et al 36 reported that amlodipine, not ARBs (any of the four agents was used in 46 patients), has an inhibitory effect on early atherosclerotic process of the carotid artery in Japanese hypertensive patients with type 2 diabetes. The Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial showed that candesartan-and amlodipine-based regimens produced no statistical differences in terms of the cerebrovascular events of high-risk Japanese hypertensive patients, but there was a significant difference in blood pressure between the two arms.…”

Section: Effects On Atherosclerosis Of the Carotid Arterymentioning

confidence: 94%

The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function and Atherosclerosis in Japanese Patients with Mild-to-Moderate Hypertension (J-ELAN) study

Yamamoto

Ozaki²,

Takayasu

et al. 2010

Hypertens Res

View full text Add to dashboard Cite

This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function. Fifty-seven patients were randomly assigned to losartan-or amlodipine-based treatment groups and were followed up for 18 months. Blood pressure was similarly reduced by both regimens. Losartan shortened the transmitral E-wave deceleration time, and amlodipine reduced LV mass index; however, there was no significant difference in the percent changes of these indices between the two groups. Mean carotid intima-media thickness (mean IMT) as well as plaque score significantly increased in the amlodipine-based regimen (pre: 1.05 ± 0.26 mm, follow-up: 1.23 ± 0.33 mm, P¼0.0015), but not in the losartan-based regimen (pre: 1.08 ± 0.35 mm, follow-up: 1.16 ± 0.52 mm, P¼non-significant). The percent increase in mean IMT in the amlodipine-based regimen tended to be large compared with the losartan-based regimen (amlodipine: 19.8 ± 23.7%, losartan: 6.9 ± 23.3%, P¼0.06). Under similar reduction of blood pressure, losartan is likely effective in protecting the progression of atherosclerosis of the carotid artery compared with amlodipine. Losartan may improve LV diastolic function, and amlodipine may attenuate LV hypertrophy; however, this study cannot make consecutive remarks about the superiority of either treatment regimen in the effects on cardiac function and geometry. This study has been registered at

show abstract

Current literature in diabetes

2009

Diabetes Metabolism Res

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 26 sections: 1 Reviews; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Obesity; 7 Prediction and Prevention; 8 Intervention: a) General; b) Care; c) Drug Therapy; d)Economics; e) Gene therapy; f) Nursing; g) Nutrition; h) Surgery; i) Transplantation; 9 Pathology and Complications: a) General; b) Cardiovascular; c) Eye disease; d) Gestational and fetal; e) Neurological; f) Podiatrical; g) Renal; 10 Endocrinology & Metabolism; 11 Experimental Studies; 12 Diagnosis and Techniques. Within each section, articles are listed in alphabetical order with respect to author

show abstract

Comparison of effects of amlodipine and angiotensin receptor blockers on the intima–media thickness of carotid arterial wall (AAA study: Amlodipine vs. ARB in atherosclerosis study)

Cited by 30 publications

References 23 publications

Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association

Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association

The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function and Atherosclerosis in Japanese Patients with Mild-to-Moderate Hypertension (J-ELAN) study

Current literature in diabetes

Contact Info

Product

Resources

About